230 related articles for article (PubMed ID: 29959569)
1. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
[TBL] [Abstract][Full Text] [Related]
2. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
4. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
[TBL] [Abstract][Full Text] [Related]
5. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
[TBL] [Abstract][Full Text] [Related]
6. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway.
Chu J; Li Y; Deng Z; Zhang Z; Xie Q; Zhang H; Zhong W; Pan B
Biomed Res Int; 2019; 2019():7201562. PubMed ID: 31355278
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
Marampon F; Gravina G; Ju X; Vetuschi A; Sferra R; Casimiro M; Pompili S; Festuccia C; Colapietro A; Gaudio E; Di Cesare E; Tombolini V; Pestell RG
Oncotarget; 2016 Feb; 7(5):5383-400. PubMed ID: 26689991
[TBL] [Abstract][Full Text] [Related]
8. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
10. c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
Gravina GL; Festuccia C; Popov VM; Di Rocco A; Colapietro A; Sanità P; Monache SD; Musio D; De Felice F; Di Cesare E; Tombolini V; Marampon F
Radiat Res; 2016 Apr; 185(4):411-22. PubMed ID: 27104757
[TBL] [Abstract][Full Text] [Related]
11. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM
Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498
[TBL] [Abstract][Full Text] [Related]
12. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
13. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
15. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
16. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
17. c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.
Liu H; Ai J; Shen A; Chen Y; Wang X; Peng X; Chen H; Shen Y; Huang M; Ding J; Geng M
Clin Cancer Res; 2017 Feb; 23(4):974-984. PubMed ID: 27401245
[No Abstract] [Full Text] [Related]
18. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
19. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
20. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]